Search Results

Glucotrack, Inc. and The Technology Partnership, announced the completion of computational modeling for Glucotrack’s implantable Continuous Blood Glucose Monitor, suggesting sensor longevity beyond three years, a year longer than the Company previously announced.

Endotronix, Inc. today announced Premarket Approval (PMA) from the U.S Food and Drug Administration (FDA) of the company’s Cordella™ Pulmonary Artery (PA) Sensor System for the treatment of New York Heart Failure (NYHA) class III heart failure patients.

Hyperfine, Inc. is proud to be the first magnetic resonance imaging technology partner in an education-centric collaboration between the International Society for Magnetic Resonance in Medicine and the Bill & Melinda Gates Foundation.

Bruker Introduces the Ingenious Novel ‘ Triceratops ’ SPR #64 Surface Plasmon Resonance System for Drug Discovery at SLAS2024.

Endotronix, Inc. today announced the submission of a Premarket Approval (PMA) application for its Cordella™ Pulmonary Artery (PA) Sensor System to the U.S. Food and Drug Administration (FDA).

Endotronix, Inc. presented 6-month results from its PROACTIVE-HF pivotal trial. PROACTIVE-HF evaluated the company’s investigational Cordella Pulmonary Artery (PA) Sensor in New York Heart Association (NYHA) class III HF patients at risk of congestion.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that Omnipod 5, compatible with both Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitor sensors, is now fully available in the U.K. and the Netherlands for individuals aged two years and older with type 1 diabetes.

Resonant, a subsidiary of Renew Biotechnologies aimed at releasing novel diagnostics for neurodegenerative diseases, recently published research revealing a novel blood biomarker of neurodegeneration.